
Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer’s Drug, Lecanemab
EXTON, PA — Frontage’s Bioanalytical team partnered with Eisai/Biogen to support the PK and PD biomarker bioanalysis of lecanemab (BAN2401) in their investigational global phase 3 study in US and China.
Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer’s Drug, Lecanemab Read More